Aligned Bio secures SEK 19.4 million to scale up its groundbreaking nanowire technology

Lund, Sweden – SmiLe company Aligned Bio has successfully completed a financing round, securing SEK 19.4 million to accelerate the development and scale up its nanowire production technology. The company has been accepted into the SmiLe incubator program. 

The nanotechnology company Aligned Bio has completed a new share issue to take its unique platform for manufacturing semiconductor nanowires toward commercialization. Both existing shareholders and new investors, including SmiLe Inject Capital, participated in the financing round. 

What makes Aligned Bio’s technology unique is its ability to detect individual molecules, significantly improving sensitivity in the analysis of biomolecules. The production of nanowires also becomes simpler and thus more cost-effective than with existing techniques. The company is now starting to scale up production. 

The potential applications are broad, but initially, the company is focusing on two key areas: single-molecule DNA analysis and highly sensitive assays, for example, point-of-care diagnostics of a specific biomarker for suspected heart attack. 

Aligned Bio is conducting projects in collaboration with leading players in the diagnostics industry, including Roche Diagnostics. The company is also collaborating with other international companies that recognize the potential to integrate nanowire technology into their products. 

”We believe that our DNA analysis technology will soon be mature enough to attract a partner who can help us bring it to market. I am very much looking forward to leveraging SmiLe’s extensive network and expertise in business development. Moreover, their laboratories and equipment give us access to the instruments we really need,” says Kenneth Harlow, CEO of Aligned Bio. 

"We are very pleased that Aligned has been so successful with its financing. This enables their groundbreaking products to reach the market sooner and benefit patients. We look forward to being involved and supporting the company's path forward,” says Ulrika Ringdahl, CEO of SmiLe Venture Hub. 

For more information, please contact:  
Ulrika Ringdahl, CEO of SmiLe Venture Hub, +46 73 656 62 32, ulrika.ringdahl@smileincubator.life,  

or

Kenneth Harlow, CEO of Aligned Bio, +46 70 777 00 43,

kenneth.harlow@alignedbio.com,

https://alignedbio.com/